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Interferon-related secretome from direct
interaction between immune cells and tumor
cells is required for upregulation of PD-L1
in tumor cells
Dear Editor,
PD-L1, also known as CD274, plays a vital role in tumor cell
related immune escape. It can be expressed on the cell
surface of many solid tumors (Brahmer et al., 2012) and
inhibits T cell proliferation and cytokine production by bind-
ing to the Tcell surface receptor programmed death 1 (PD-1)
or B7-1 (McClanahan et al., 2015). In 2013, targeting PD-1/
PD-L1 signaling for cancer immunotherapy was selected as
the No.1 scientiﬁc breakthrough of the year by the editors of
Science. Interferons (IFNs) are a group of pleiotropic
cytokines, demonstrated anti-viral, anti-tumor, and immune
regulatory functions (York et al., 2015). Type I interferon
binds a heterodimeric receptor composed of IFNAR1 and
IFNAR2. This activates a canonical JAK/STAT signaling
pathway that ultimately induces a set of interferon-stimulated
genes to exert its biological activity (Ejlerskov et al., 2015).
Recently, PD-L1 was reported to be downstream of IFN
signaling in human oral squamous carcinoma, melanoma,
and human acute myeloid leukemia blast cells (Chen et al.,
2012; Furuta et al., 2014; Kronig et al., 2014).
The tumor microenvironment plays an important role in
tumor growth and metastasis. Different components of the
tumor microenvironment such as T cells, B cells, NK cells,
dendritic cells, mast cells, granulocytes, Treg cells, myeloid
derived suppressor cells (MDSC), and tumor associated
macrophages (TAM) are recruited by different pathways
(Joyce and Fearon, 2015). Tumor cells have been shown to
upregulate PD-L1 after interacting with inﬁltrating immune
cells (Cho et al., 2011; Hou et al., 2014), but the mechanism
by which this occurs is not well understood. In this study, we
found that PD-L1 upregulation in tumors was dependent on
direct interaction with immune cells and was driven by a
secreted factor such as type I interferon after cell-cell
contact.
Previous studies have demonstrated a positive correla-
tion between tumor-inﬁltrating immune cells and elevated
PD-L1 expression in tumor cells, but the mechanism by
which this occurs is poorly understood. To investigate this,
we co-cultured murine B16F10 melanoma cells with syn-
geneic splenocytes for 48 h. In addition, to determine whe-
ther direct cell contact is required for immune cell-mediated
PD-L1 expression, the two types of cells were separated by
a transwell-membrane that blocked their direct cell-cell
interactions. Furthermore, another condition was tested in
which B16F10 cells and immune cells were co-cultured in
the plate and B16F10 cells were cultured in the transwell
insert (Fig. 1A). Then the non-adherent immune cells were
removed and B16F10 cells were harvested and analyzed for
PD-L1 expression by ﬂow cytometry. PD-L1 was more highly
expressed in B16F10 cells that were co-cultured with
splenocytes than in those cultured alone (Fig. 1B). However,
PD-L1 expression was not increased in B16F10 cells sep-
arated from the splenocytes by a transwell membrane. We
also found that a B16F10-splenocyte co-culture was able to
induce PD-L1 in tumor cells separated from the co-culture by
a transwell membrane (Fig. 1B). These effects were also
observed in PD-L1 mRNA level changes by qPCR (Fig. 1C).
These results suggested that active factors were secreted
into the supernatant after the direct cell-cell interaction that
was able to induce PD-L1 expression in tumor cells.
To identify whether the regulation of PD-L1 was indeed
driven by a secreted factor, B16F10 cells and splenocytes
were co-cultured for 48 h. The supernatant was collected
and centrifuged, and then used to treat B16F10 cells
independently. The corresponding supernatant derived
from B16F10 cells and splenocytes alone was also used to
treat B16F10 cells as control groups (Fig. 1D). After 24 h,
B16F10 cells treated with supernatant from the co-culture
expressed more PD-L1 than cells treated with supernatant
from the control mono-cultures (Fig. 1E and 1F). In addition,
co-cultures of B16F10 cells with bone marrow (BM)-derived
cells (Fig. 1G) or lymph node (LN)-derived cells also
upregulated PD-L1 expression (Fig. 1H). To determine
whether a similar effect would be seen in other types of
cancer cells, additional studies on MC38 and Hepa1-6 cells
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were performed and the same result was obtained
(Fig. S1).
Some evidence suggests that cellular components such
as tumor cell-derived antigen or other cellular components
may also induce PD-L1 expression. To examine these pos-
sibilities, we tested whether B16F10 cell-related tumor anti-
gen can stimulate immune cells to secrete type I IFN and
whether immune cell-derived components can stimulate
tumor cells to upregulate PD-L1. Thus, living immune cells
were cultured with B16F10 lysate and live B16F10 tumor
cells were cultured with splenocyte lysate. We found that
neither lysate can induce PD-L1 expression (Fig. 1I and 1J).
These results demonstrated that cell lysate is not sufﬁcient to
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It has been reported that PD-L1 expression is induced by
IFN signaling. Here we conﬁrmed that the interferon signal
was involved. The mRNA expression level of interferon
stimulated genes such as IRF7 and ISG15 was signiﬁcantly
upregulated by the supernatant derived from the co-culture
of B16F10 cells with bone marrow cells, lymph node cells, or
splenocytes (Fig. 2A–C). Moreover, the phosphorylation of
STAT1 and STAT3 were increased by supernatant treatment
(Fig. 2D). Further, it was observed that co-culture of B16F10
and immune cells contributed to more IFN-α and IFN-β
release in their supernatant (Fig. S2A and S2B). It is known
that interferons (IFN-α, IFN-β, and IFN-γ) induce PD-L1 in
tumor cells and the above data suggested that interferon
signaling may mediate PD-L1 expression in this system. To
determine whether the expression of PD-L1 can be induced
by type I IFN in B16F10 cells, we treated B16F10 cells with
IFN-β and the ﬂow cytometry results showed that IFN-β can
induce PD-L1 in a concentration-dependent manner
(Fig. S3A). Additionally, by using human ﬁbrosarcoma
2fTGH cells (ifnar2+/+) and the mutant U5A cells (ifnar2-/-)
that lack of type I interferon receptor subunit ifnar2, we found
that IFN-α induced PD-L1 in 2fTGH cells, but failed to induce
PD-L1 in U5A cells (Fig. S3B). These data suggested that
the induction of PD-L1 by co-culture supernatant may be
interferon receptor dependent. To test this hypothesis, anti-
IFNAR1 antibody was added to the co-culture medium. We
found that the neutralizing antibody reduced splenocyte-in-
duced PD-L1 expression in B16F10 cells (Fig. 2E). The
suppression of PD-L1 expression by anti-IFNAR1 was fur-
ther conﬁrmed by transwell and supernatant transfer assays
(Fig. 2F and 2G). Similarly, these results were observed in
BM and LN cell co-culture experiments (Fig. S4). However,
in splenocytes and LN cell co-culture, anti-IFNAR1 antibody
only partially blocked PD-L1 expression, suggesting that
other secreted factors were involved in stimulating the PD-L1
expression. After testing the different supernatant by
cytokines/chemokines microarray, higher IFN-γ, IL-6 (well
proved for PD-L1 regulation), and G-CSF, Leptin, MIG, MCP-
5, MIP-1a (ﬁrstly observed here may related to PD-L1 reg-
ulation) expression were found in the supernatant from co-
culture of B16F10 and immune cells compared to super-
natant from B16F10 (Figs. 2H, S5A, and S5B). Additionally,
we found that after adding the anti-IFNAR1 antibody, PD-L1
expression in B16F10 cells were unable to response to type I
IFN stimulation (Fig. S3C). However, IFN-γ still induced PD-
L1 expression in B16F10 cells treated with and without anti-
IFNAR1 antibody (Fig. S3D). The above ﬁndings suggested
a working model in which direct contaction between immune
cells and tumor cells induces the secretion of factors
including type I/II interferons, then these factors promote PD-
L1 expression in both contacted and uncontacted tumor cells
(Fig. 2I).
PD-L1 is expressed in multiple different tumor cells that
suppress anti-tumor immunity in the tumor microenviron-
ment. By binding to its receptor PD-1 on T cells, PD-L1
inhibits the T cell-mediated immune response. Targeting PD-
L1/PD-1 signaling has been shown to be a highly efﬁcacious
cancer immunotherapy (Brahmer et al., 2012; Topalian et al.,
2012). Several signaling pathways have been shown to
upregulate PD-L1 in tumor cells, including NF-κB, AKT, IFN,
and IL-6 (Chen et al., 2012; Jin et al., 2013; Gowrishankar
et al., 2015; Lastwika et al., 2016). However, the factors
promoting elevated PD-L1 expression in the tumor
microenvironment have not been thoroughly elucidated.
In this study, we demonstrated that tumor cell PD-L1
expression is elevated by co-culture with immune cells, and
this effect is dependent on the direct interaction between
tumor and immune cells. A previous study revealed that
CD11b+ myeloid cells adhered to the surface of tumor cells
to induce tumor PD-L1 expression through the p38 pathway
(Noh et al., 2015). Here, we found that direct cell-cell inter-
actions are required for the production of the secreted fac-
tors that induce PD-L1 expression in B16F10 cells.
Additionally, the secretome including IFNs induce the PD-L1
expression. However, PD-L1 expression can be partially
blocked with anti-IFNAR1 antibody in splenocytes and LN
cells co-culture models. These data suggested the possible
contribution of other molecules in the regulation of PD-L1
expression by protein microassay. But in our study, which
cell population secreted IFNs and which type of immune
Figure 1. Upregulation of PD-L1 in tumor cells required
secreted factors from living cells after direct cell-cell
interactions. (A) Schematic diagram of the different co-culture
conditions of tumor cells and immune cells (primary spleno-
cytes, bone marrow (BM)-derived cells, or lymph node (LN)-
derived cells). Tumor cells were directly mixed with immune
cells (Direct co-culture) or not (Mock). In the transwell co-culture
system, tumor cells were seeded onto the upper insert with the
lower compartment containing immune cells (Transwell culture)
or a mixture of immune cells and tumor cells (Transwell co-
culture). (B and C) Expression of PD-L1 in B16F10 cells was
determined by ﬂow cytometry (B) and RT-qPCR (C).
(D) Schematic diagram for treatment of tumor cells with
supernatant from co-cultured tumor cells and splenocytes
(Co-culture supernatant transfer), tumor cells alone (Mock) or
splenocytes alone (Culture supernatant transfer) as control
groups. (E and F) Expression of PD-L1 was determined by ﬂow
cytometry (E) and RT-qPCR (F). (G and H) PD-L1 expression
was determined by ﬂow cytometry in B16F10 cells by co-
culturing with BM (G) or LN cells (H). (I) B16F10 tumor cells
were treated for 24 h with supernatant from a 48 h culture of live
B16F10 cells (Mock), live splenocytes with B16F10 lysate
(supernatant transfer from splenocytes treated B16F10 lysate),
live B16F10 cells and live splenocytes (Co-culture supernatant
transfer), or B16F10 cell lysate (supernatant transfer from
B16F10 lysate). (J) Similarly, B16F10 tumor cells were treated
with supernatant from live B16F10 cells with splenocyte lysate
(supernatant transfer from B16F10 treated splenocytes lysate),
or splenocyte lysate (supernatant transfer from splenocytes
lysate). PD-L1 expression was measured by ﬂow cytometry.
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cells play a key point for cell-cell contaction still need further
study.
On the basis of others' and our studies, we think that
CD11b+ cells may phagocytose tumor cells to trigger pro-
duction of type I IFN in STING signaling-dependent manner.
Blockade of PD-1/PD-L1 signaling with monoclonal anti-
bodies has been demonstrated to be a promising new
immunotherapy. However, this therapy has a limited role on
extending survival time and can lead to inﬂammatory side
effects called immune-related adverse events (irAEs) in
other normal tissues (Brahmer et al., 2012). Our ﬁndings
suggest an alternative way to ﬁnd speciﬁc inhibitors to limit
PD-L1 expression in tumor cells by blocking its up-stream
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combination with PD-L1 antibodies to achieve better effect
for cancer therapy.
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